Clinical Trial: A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of VSA012 Injection versus Eculizumab in Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Previously Received Complement Inhibitors (China)

China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of VSA012 Injection versus Eculizumab in Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Previously Received Complement Inhibitors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135778

Registration Time: 2026/11/02

Type: Interventional study

Primary Sponsor: Peking Union Medical College Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=347315

Published by HT Digital Content Services with permission from Heal...